{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:49:24Z","timestamp":1789616964893,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Activation of TLR2 or TLR4 by endogenous ligands such as high mobility group box 1 (HMGB1) may mediate inflammation causing diabetic kidney injury. We determined whether blockade of HMGB1 signaling by: (1) supra-physiological production of endogenous secretory Receptor for Advanced Glycation End-products (esRAGE), a receptor for HMGB1; (2) administration of HMGB1 A Box, a specific competitive antagonist, would inhibit development of streptozotocin induced diabetic nephropathy (DN). Wild-type diabetic mice developed albuminuria, glomerular injuries, interstitial fibrosis and renal inflammation. Using an adeno-associated virus vector, systemic over-expression of esRAGE afforded significant protection from all parameters. No protection was achieved by a control vector which expressed human serum albumin. Administration of A Box was similarly protective against development of DN. To determine the mechanism(s) of protection, we found that whilst deficiency of TLR2, TLR4 or RAGE afforded partial protection from development of DN, over-expression of esRAGE provided additional protection in TLR2<jats:sup>\u2212\/\u2212<\/jats:sup>, modest protection against podocyte damage only in TLR4<jats:sup>\u2212\/\u2212<\/jats:sup> and no protection in RAGE<jats:sup>\u2212\/\u2212<\/jats:sup> diabetic mice, suggesting the protection provided by esRAGE was primarily through interruption of RAGE and TLR4 pathways. We conclude that strategies to block the interaction between HMGB1 and its receptors may be effective in preventing the development of DN.<\/jats:p>","DOI":"10.1038\/s41598-018-26637-5","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T13:40:19Z","timestamp":1527082819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice"],"prefix":"10.1038","volume":"8","author":[{"given":"Xiaochen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth G. D.","family":"Stribos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Lianne","family":"Messchendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yik W.","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moumita","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eithne C.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian E.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra F.","family":"Sharland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0527-898X","authenticated-orcid":false,"given":"Steven J.","family":"Chadban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"26637_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrendo.2013.184","volume":"9","author":"D Fineberg","year":"2013","unstructured":"Fineberg, D., Jandeleit-Dahm, K. A. & Cooper, M. E. Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol 9, 713\u2013723 (2013).","journal-title":"Nat Rev Endocrinol"},{"key":"26637_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","volume":"12","author":"MC Thomas","year":"2016","unstructured":"Thomas, M. C., Cooper, M. E. & Zimmet, P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 12, 73\u201381 (2016).","journal-title":"Nat Rev Nephrol"},{"key":"26637_CR3","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/ATVBAHA.111.228924","volume":"31","author":"S Devaraj","year":"2011","unstructured":"Devaraj, S. et al. Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol 31, 1796\u20131804 (2011).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"26637_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1681\/ASN.2010111210","volume":"23","author":"M Lin","year":"2012","unstructured":"Lin, M. et al. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 23, 86\u2013102 (2012).","journal-title":"J Am Soc Nephrol"},{"key":"26637_CR5","first-page":"481","volume":"7","author":"J Ma","year":"2014","unstructured":"Ma, J. et al. Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. Int J Clin Exp Pathol 7, 481\u2013495 (2014).","journal-title":"Int J Clin Exp Pathol"},{"key":"26637_CR6","doi-asserted-by":"publisher","first-page":"e97985","DOI":"10.1371\/journal.pone.0097985","volume":"9","author":"J Ma","year":"2014","unstructured":"Ma, J. et al. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One 9, e97985 (2014).","journal-title":"PLoS One"},{"key":"26637_CR7","doi-asserted-by":"publisher","first-page":"F143","DOI":"10.1152\/ajprenal.00398.2012","volume":"305","author":"H Mudaliar","year":"2013","unstructured":"Mudaliar, H. et al. The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. Am J Physiol Renal Physiol 305, F143\u2013154 (2013).","journal-title":"Am J Physiol Renal Physiol"},{"key":"26637_CR8","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/01.ASN.0000121781.89599.16","volume":"15","author":"HJ Anders","year":"2004","unstructured":"Anders, H. J., Banas, B. & Schlondorff, D. Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15, 854\u2013867 (2004).","journal-title":"J Am Soc Nephrol"},{"key":"26637_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nri1391","volume":"4","author":"S Akira","year":"2004","unstructured":"Akira, S. & Takeda, K. Toll-like receptor signalling. Nat Rev Immunol 4, 499\u2013511 (2004).","journal-title":"Nat Rev Immunol"},{"key":"26637_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/MED.0b013e3283372819","volume":"17","author":"SC Pino","year":"2010","unstructured":"Pino, S. C., Kruger, A. J. & Bortell, R. The role of innate immune pathways in type 1 diabetes pathogenesis. Curr Opin Endocrinol Diabetes Obes 17, 126\u2013130 (2010).","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"26637_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/978-90-481-3271-3_25","volume":"654","author":"D Zipris","year":"2010","unstructured":"Zipris, D. Toll-like receptors and type 1 diabetes. Adv Exp Med Biol 654, 585\u2013610 (2010).","journal-title":"Adv Exp Med Biol"},{"key":"26637_CR12","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s001250051058","volume":"41","author":"JC Pickup","year":"1998","unstructured":"Pickup, J. C. & Crook, M. A. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41, 1241\u20131248 (1998).","journal-title":"Diabetologia"},{"key":"26637_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1681\/ASN.2007091048","volume":"19","author":"JF Navarro-Gonzalez","year":"2008","unstructured":"Navarro-Gonzalez, J. F. & Mora-Fernandez, C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19, 433\u2013442 (2008).","journal-title":"J Am Soc Nephrol"},{"key":"26637_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1749-6632.2011.06320.x","volume":"1243","author":"R Ramasamy","year":"2011","unstructured":"Ramasamy, R., Yan, S. F. & Schmidt, A. M. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 1243, 88\u2013102 (2011).","journal-title":"Ann N Y Acad Sci"},{"key":"26637_CR15","first-page":"351","volume":"3","author":"L Lin","year":"2006","unstructured":"Lin, L. RAGE on the Toll Road? Cell Mol Immunol 3, 351\u2013358 (2006).","journal-title":"Cell Mol Immunol"},{"key":"26637_CR16","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1096\/fj.08-109033","volume":"22","author":"A Raucci","year":"2008","unstructured":"Raucci, A. et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716\u20133727 (2008).","journal-title":"FASEB J"},{"key":"26637_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2119\/molmed.2012.00309","volume":"19","author":"T Takahashi","year":"2013","unstructured":"Takahashi, T. et al. Bone-targeting endogenous secretory receptor for advanced glycation end products rescues rheumatoid arthritis. Mol Med 19, 183\u2013194 (2013).","journal-title":"Mol Med"},{"key":"26637_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1196\/annals.1333.064","volume":"1043","author":"Y Yamamoto","year":"2005","unstructured":"Yamamoto, Y. et al. Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann N Y Acad Sci 1043, 562\u2013566 (2005).","journal-title":"Ann N Y Acad Sci"},{"key":"26637_CR19","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1172\/JCI200418704","volume":"113","author":"B Liliensiek","year":"2004","unstructured":"Liliensiek, B. et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. Journal of Clinical Investigation 113, 1641\u20131650 (2004).","journal-title":"Journal of Clinical Investigation"},{"key":"26637_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nri1594","volume":"5","author":"MT Lotze","year":"2005","unstructured":"Lotze, M. T. & Tracey, K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5, 331\u2013342 (2005).","journal-title":"Nat Rev Immunol"},{"key":"26637_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1073\/pnas.2434651100","volume":"101","author":"H Yang","year":"2004","unstructured":"Yang, H. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101, 296\u2013301 (2004).","journal-title":"Proc Natl Acad Sci USA"},{"key":"26637_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-3083.2008.02194.x","volume":"69","author":"Q Gong","year":"2009","unstructured":"Gong, Q. et al. Protective effect of antagonist of high-mobility group box 1 on lipopolysaccharide-induced acute lung injury in mice. Scand J Immunol 69, 29\u201335 (2009).","journal-title":"Scand J Immunol"},{"key":"26637_CR23","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1161\/CIRCULATIONAHA.108.769331","volume":"117","author":"M Andrassy","year":"2008","unstructured":"Andrassy, M. et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117, 3216\u20133226 (2008).","journal-title":"Circulation"},{"key":"26637_CR24","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1002\/art.27590","volume":"62","author":"T Ostberg","year":"2010","unstructured":"Ostberg, T. et al. Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis Rheum 62, 2963\u20132972 (2010).","journal-title":"Arthritis Rheum"},{"key":"26637_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1369\/0022155412465073","volume":"60","author":"SO Kolset","year":"2012","unstructured":"Kolset, S. O., Reinholt, F. P. & Jenssen, T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem 60, 976\u2013986 (2012).","journal-title":"J Histochem Cytochem"},{"key":"26637_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1523-1755.2004.00367.x","volume":"65","author":"F Chow","year":"2004","unstructured":"Chow, F., Ozols, E., Nikolic-Paterson, D. J., Atkins, R. C. & Tesch, G. H. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 65, 116\u2013128 (2004).","journal-title":"Kidney Int"},{"key":"26637_CR27","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1172\/JCI31008","volume":"117","author":"H Wu","year":"2007","unstructured":"Wu, H. et al. TLR4 activation mediates kidney ischemia\/reperfusion injury. J Clin Invest 117, 2847\u20132859 (2007).","journal-title":"J Clin Invest"},{"key":"26637_CR28","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1172\/JCI22832","volume":"115","author":"JC Leemans","year":"2005","unstructured":"Leemans, J. C. et al. Renal-associated TLR2 mediates ischemia\/reperfusion injury in the kidney. J Clin Invest 115, 2894\u20132903 (2005).","journal-title":"J Clin Invest"},{"key":"26637_CR29","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1681\/ASN.2007090982","volume":"19","author":"B Zhang","year":"2008","unstructured":"Zhang, B., Ramesh, G., Uematsu, S., Akira, S. & Reeves, W. B. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 19, 923\u2013932 (2008).","journal-title":"J Am Soc Nephrol"},{"key":"26637_CR30","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1681\/ASN.2005111167","volume":"17","author":"HJ Brown","year":"2006","unstructured":"Brown, H. J., Sacks, S. H. & Robson, M. G. Toll-like receptor 2 agonists exacerbate accelerated nephrotoxic nephritis. J Am Soc Nephrol 17, 1931\u20131939 (2006).","journal-title":"J Am Soc Nephrol"},{"key":"26637_CR31","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2006060634","volume":"18","author":"HJ Brown","year":"2007","unstructured":"Brown, H. J. et al. Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2. J Am Soc Nephrol 18, 1732\u20131739 (2007).","journal-title":"J Am Soc Nephrol"},{"key":"26637_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cyto.2010.02.021","volume":"51","author":"W Huang","year":"2010","unstructured":"Huang, W., Tang, Y. & Li, L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 51, 119\u2013126 (2010).","journal-title":"Cytokine"},{"key":"26637_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.20042614","volume":"201","author":"A Tsung","year":"2005","unstructured":"Tsung, A. et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201, 1135\u20131143 (2005).","journal-title":"J Exp Med"},{"key":"26637_CR34","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1681\/ASN.2009101048","volume":"21","author":"H Wu","year":"2010","unstructured":"Wu, H. et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 21, 1878\u20131890 (2010).","journal-title":"J Am Soc Nephrol"},{"key":"26637_CR35","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.4049\/jimmunol.165.6.2950","volume":"165","author":"E Abraham","year":"2000","unstructured":"Abraham, E., Arcaroli, J., Carmody, A., Wang, H. & Tracey, K. J. HMG-1 as a mediator of acute lung inflammation. J Immunol 165, 2950\u20132954 (2000).","journal-title":"J Immunol"},{"key":"26637_CR36","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00125-009-1394-8","volume":"52","author":"S Devaraj","year":"2009","unstructured":"Devaraj, S., Dasu, M. R., Park, S. H. & Jialal, I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 52, 1665\u20131668 (2009).","journal-title":"Diabetologia"},{"key":"26637_CR37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.20045","volume":"39","author":"S Zeng","year":"2004","unstructured":"Zeng, S. et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 39, 422\u2013432 (2004).","journal-title":"Hepatology"},{"key":"26637_CR38","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/2012","volume":"4","author":"L Park","year":"1998","unstructured":"Park, L. et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4, 1025\u20131031 (1998).","journal-title":"Nat Med"},{"key":"26637_CR39","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2337\/db05-1375","volume":"55","author":"T Shoji","year":"2006","unstructured":"Shoji, T. et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 55, 2245\u20132255 (2006).","journal-title":"Diabetes"},{"key":"26637_CR40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00467-011-1988-5","volume":"27","author":"C Giannini","year":"2012","unstructured":"Giannini, C. et al. The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood. Pediatr Nephrol 27, 269\u2013275 (2012).","journal-title":"Pediatr Nephrol"},{"key":"26637_CR41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1600-6143.2007.01734.x","volume":"7","author":"Y Huang","year":"2007","unstructured":"Huang, Y. et al. Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 7, 799\u2013808 (2007).","journal-title":"Am J Transplant"},{"key":"26637_CR42","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/mt.2015.92","volume":"23","author":"KY Mak","year":"2015","unstructured":"Mak, K. Y. et al. ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice. Mol Ther 23, 1434\u20131443 (2015).","journal-title":"Mol Ther"},{"key":"26637_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.trre.2009.04.001","volume":"23","author":"JM Laurence","year":"2009","unstructured":"Laurence, J. M. et al. Gene therapy in transplantation. Transplantation Reviews 23, 159\u2013170 (2009).","journal-title":"Transplantation Reviews"},{"key":"26637_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1152\/jappl.1962.17.2.343","volume":"17","author":"ER Weibel","year":"1962","unstructured":"Weibel, E. R. & Gomez, D. M. A principle for counting tissue structures on random sections. J Appl Physiol 17, 343\u2013348 (1962).","journal-title":"J Appl Physiol"},{"key":"26637_CR45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1440-1797.2007.00855.x","volume":"12","author":"GK Rangan","year":"2007","unstructured":"Rangan, G. K. & Tesch, G. H. Quantification of renal pathology by image analysis. Nephrology (Carlton) 12, 553\u2013558 (2007).","journal-title":"Nephrology (Carlton)"},{"key":"26637_CR46","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1007\/s00125-010-1757-1","volume":"53","author":"AK Lim","year":"2010","unstructured":"Lim, A. K. et al. Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury. Diabetologia 53, 1772\u20131782 (2010).","journal-title":"Diabetologia"},{"key":"26637_CR47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/00007890-198610000-00004","volume":"42","author":"DL McWhinnie","year":"1986","unstructured":"McWhinnie, D. L. et al. Morphometric analysis of cellular infiltration assessed by monoclonal antibody labeling in sequential human renal allograft biopsies. Transplantation 42, 352\u2013358 (1986).","journal-title":"Transplantation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26637-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26637-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26637-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T05:48:00Z","timestamp":1671601680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26637-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["26637"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-26637-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"26 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8319"}}